|
Match
|
Document |
Document Title |
|
|
US20090317479 |
NANOPARTICLES CONTAINING WATER-SOLUBLE NON-PEPTIDE LOW-MOLECULAR WEIGHT DRUG
Drug-containing nanoparticles are provided that enable effective targeting and sustained-release of a water-soluble, non-peptide, low-molecular weight drug and cause reduced accumulation of the...
|
|
|
US20090252716 |
METHODS FOR IDENTIFYING NUCLEAR RECEPTOR/LIGAND COMBINATIONS FOR TARGETING BRAIN TUMOR STEM CELLS AND FOR THEIR USE
An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's),...
|
|
|
US20090197962 |
SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY
Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein.
|
|
|
US20090155338 |
Chronotherapeutic Ocular Delivery System Comprising a Combination of Prostaglandin and a Beta-Blocker for Treating Primary Glaucoma
Chronotherapeutic delivery system for treating primary open-angle glaucoma, comprising a delivery system incorporating pharmaceutical products for delivery to an eye in the treatment of primary...
|
|
|
US20090124688 |
Prostaglandin reductase inhibitors
A method of inhibiting 15-keto prostaglandin-Δ 13 -reductase 2 by contacting 15-keto prostaglandin-Δ 13 -reductase 2 with an aryl compound of Formula (I), (II), (III), or (IV) shown herein. Also...
|
|
|
US20090118373 |
Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
A natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be...
|
|
|
US20090088473 |
METHOD FOR SCREENING OF PROSTAGLANDIN COMPOUNDS COMPRISING AN OPTIMAL FORMULATION FOR THE ENHANCEMENT OF HAIR GROWTH AND THE STIMULATION OF FOLLICULAR ANAGEN AND FORMULATIONS RESULTING THEREFROM
A method for developing Prostaglandin F 2α analogs for enhancing and sustaining the growth of eye lashes. The exemplary method first provides a method for determining the ability of a FP receptor...
|
|
|
US20090048312 |
PLANT PATHOGEN RESISTANCE
Azelaic acid or its derivatives or analogs induce a robust and a speedier defense response against pathogens in plants. Azelaic acid treatment alone does not induce many of the known...
|
|
|
US20080287544 |
Method for Screening Substance by Measuring PPAR DELTA Activating Effect and Agent
The present invention provides a method for screening a substance having a thermogenesis enhancing effect containing a compound having an effect activating PPARδ, an agent containing the compound,...
|
|
|
US20080287879 |
SYSTEM AND METHOD FOR TREATING ERECTILE DYSFUNCTION
A treatment for male erectile dysfunction comprising separately storing a lyophilized composition of vasoactive agents and a carrier gel, mixing said lyophilized composition of vasoactive agents...
|
|
|
US20080207759 |
METHOD FOR PROTECTING MITOCHONDRIA
The present invention relates to a method for protecting mitochondria from damage in a mammalian subject, which comprises administering an effective amount of a prostaglandin compound to a subject...
|
|
|
US20080200550 |
Inhibition of Hiv-1 Replication by Disruption of the Processing of the Viral Capsid-Spacer Peptide 1 Protein
Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences...
|
|
|
US20080175831 |
NEUROPROTECTION BY BLOOD FLOW STABILIZATION
A treatment is disclosed for alleviation or prevention of abnormal blood flow to various organs such as the eye, brain, kidneys, heart, feet and other tissues of organs with fine vascular networks...
|
|
|
US20080167379 |
Ointment
An ointment containing a compound represented by formula (I):
[wherein R 1 represents any group of
a group represented by the formula:
|
|
|
US20080132543 |
Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists
A compound comprising a prodrug of a prostaglandin EP 4 agonist, wherein said prodrug is an ester, ether, or amide of a carbohydrate; or said prodrug is an ester, ether, or amide of an amino acid...
|
|
|
US20080114025 |
Cardiovascular compositions and methods using combinations of anti-platelet agents
A method and composition for inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The...
|
|
|
US20080113024 |
Methods and compositions for treating platelet-related disorders
Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and...
|
|
|
US20080113973 |
Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2
The invention is directed to methods and compositions that can be used in the treatment of inflammation, pain and cardiovascular disorders. Methods and compositions are described involving the...
|
|
|
US20080107738 |
Ophthalmic Emulsions Containing Prostaglandins
Cationic ophthalmic oil-in-water type emulsions, include colloid particles having an oily core surrounded by an interfacial film, the emulsion including at least one cationic agent and at least one...
|
|
|
US20080103184 |
COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS USING NON-NATURALLY OCCURRING PROSTAGLANDINS
A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss,...
|
|
|
US20080090911 |
Stabilized prostaglandin E composition
A prostaglandin E composition comprises are substantially free from C 1 -C 4 alcohols and include the prostaglandin E compound together with a (C 1 -C 4 )-alkyl (C 8 -C 22 ) carboxylic ester...
|
|
|
US20080069883 |
PROSTAGLANDIN COMPOSITIONS AND METHODS FOR THE TREATMENT OF VASOSPASM
Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are...
|
|
|
US20080064717 |
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
The present invention relates to compounds of formula (I):
wherein R 1 , R 3 , X, Q, Z, A, 9, m, and n are defined herein Pharmaceutical compositions and methods for treating DGAT-1...
|
|
|
US20080058363 |
PHARMACEUTICAL COMPOSITION FOR TREATING FECAL INCONTINENCE AND ANAL ITCH
Fecal incontinence and anal itch can be treated by administration, more particularly by local application to the anus, of an α adrenergic blocker, nitric oxide synthase inhibitor, prostaglandin F...
|
|
|
US20080020041 |
Enteric Coated Compositions that Release Active Ingredient(s) in Gastric Fluid and Intestinal Fluid
Embodiments of a pharmaceutical formulation comprising an enteric material are disclosed. The embodiments release at least a portion of an active ingredient upon contacting gastric fluid. The...
|
|
|
US20080004310 |
LYOPHILIZED PHARMACEUTICAL COMPOSITION
A stable pharmaceutical composition with increased solubility that includes at least one lyophilized compound that is papaverine, phentolamine or alprostadil.
|